JP2007500714A5 - - Google Patents

Download PDF

Info

Publication number
JP2007500714A5
JP2007500714A5 JP2006522068A JP2006522068A JP2007500714A5 JP 2007500714 A5 JP2007500714 A5 JP 2007500714A5 JP 2006522068 A JP2006522068 A JP 2006522068A JP 2006522068 A JP2006522068 A JP 2006522068A JP 2007500714 A5 JP2007500714 A5 JP 2007500714A5
Authority
JP
Japan
Prior art keywords
composition
compound
disorder
effective amount
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006522068A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007500714A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/024525 external-priority patent/WO2005012303A1/en
Publication of JP2007500714A publication Critical patent/JP2007500714A/ja
Publication of JP2007500714A5 publication Critical patent/JP2007500714A5/ja
Pending legal-status Critical Current

Links

JP2006522068A 2003-07-31 2004-07-29 勃起不全を処置するのに有用なキサンチンホスホジエステラーゼ５インヒビターの代謝物およびそれらの誘導体 Pending JP2007500714A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49221803P 2003-07-31 2003-07-31
PCT/US2004/024525 WO2005012303A1 (en) 2003-07-31 2004-07-29 Metabolite of xanthine phosphodiesterase 5 inhibitor and derivatives thereof useful for treatment of erectile dysfunction

Publications (2)

Publication Number Publication Date
JP2007500714A JP2007500714A (ja) 2007-01-18
JP2007500714A5 true JP2007500714A5 (enExample) 2007-09-13

Family

ID=34115611

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006522068A Pending JP2007500714A (ja) 2003-07-31 2004-07-29 勃起不全を処置するのに有用なキサンチンホスホジエステラーゼ５インヒビターの代謝物およびそれらの誘導体

Country Status (10)

Country Link
US (1) US7312223B2 (enExample)
EP (1) EP1648895B1 (enExample)
JP (1) JP2007500714A (enExample)
CN (1) CN1860119A (enExample)
AT (1) ATE363483T1 (enExample)
CA (1) CA2533715A1 (enExample)
DE (1) DE602004006756T2 (enExample)
ES (1) ES2284056T3 (enExample)
MX (1) MXPA06001195A (enExample)
WO (1) WO2005012303A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
CN100497336C (zh) * 2002-05-31 2009-06-10 先灵公司 制备黄嘌呤磷酸二酯酶v抑制剂及其前体的方法
US8299083B2 (en) * 2004-08-17 2012-10-30 The Johns Hopkins University PDE5 inhibitor compositions and methods for treating cardiac indications
KR20090087795A (ko) * 2008-02-13 2009-08-18 한양대학교 산학협력단 혈관 재협착 예방 및 치료를 위한 약학 조성물 및 이를포함하는 스텐트
CN101747282A (zh) 2008-12-10 2010-06-23 上海特化医药科技有限公司 一类含有嘧啶酮苯基的化合物、其药物组合物及其制备方法和用途
US20100261737A1 (en) * 2009-04-10 2010-10-14 Medtronic Vascular, Inc. Method of Treating Erectile Dysfunction
US20140271680A1 (en) 2011-08-12 2014-09-18 Universite Paris-Est Creteil Val De Marne Methods and pharmaceutical compositions for treatment of pulmonary hypertension
WO2013054153A1 (en) 2011-10-11 2013-04-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Nutlin compounds for use in he treatment of pulmonary hypertension
CN106770618A (zh) * 2015-11-20 2017-05-31 中国康复研究中心 一种建立急性缺血性脑卒中特征蛋白的质谱模型的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8906792D0 (en) * 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
IL98559A0 (en) * 1990-06-21 1992-07-15 Schering Corp Polycyclic guanine derivatives
GB9020959D0 (en) * 1990-09-26 1990-11-07 Beecham Group Plc Novel compounds
US5409934A (en) * 1990-12-21 1995-04-25 Smith; David G. Xanthine derivatives
GB9210839D0 (en) 1992-05-21 1992-07-08 Smithkline Beecham Plc Novel compounds
CA2156918A1 (en) * 1993-02-26 1994-09-01 Deen Tulshian 2-benzyl-polycyclic guanine derivatives and process for preparing them
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
MXPA04011865A (es) * 2002-05-31 2005-03-31 Schering Corp Polimorfos inhibidores de xantina fosfodiesterasa v.
CN100497336C (zh) * 2002-05-31 2009-06-10 先灵公司 制备黄嘌呤磷酸二酯酶v抑制剂及其前体的方法

Similar Documents

Publication Publication Date Title
JP7688681B2 (ja) アルドース還元酵素阻害剤およびその使用方法
CN102256984B (zh) 制备二胺衍生物的方法
CN101065370B (zh) 具有β-2-肾上腺素受体激动剂活性的5-羟基-苯并噻唑衍生物
JP2007500714A5 (enExample)
CN105732640B (zh) 醛糖还原酶抑制剂及其用途
JP2000072773A (ja) プリン誘導体
KR20090040259A (ko) 3-(1,3-벤조디옥솔-5-일)-6-(4-시클로프로필피페라진-1-일)-피리다진, 그것의 염과 용매화합물 및 그것의 히스타민 ｈ3 수용체 안타고니스트로서의 용도
CN101531653B (zh) 3-(4-氨基-1-氧代-1,3-二氢异吲哚-2-基)哌啶-2,6-二酮及其衍生物的盐或盐的多晶型物及其制备和应用
JPH11508920A (ja) ２，７―置換オクタヒドロ―ピロロ［１，２―ａ］ピラジン誘導体
CN1166677C (zh) 噻吩a2a受体激动剂
CN109761983B (zh) 一种利格列汀的制备方法
ATE363483T1 (de) Metabolit eines xanthinphosphodiesterase-5- inhibitors und derivate davon, die sich zur behandlung von errektionsstörungen eignen
JP2006516565A (ja) 治療薬を製造するための２−アミノ−２ｈ−キナゾリン誘導体の使用
JP5661177B2 (ja) ヘキサヒドロピロロ［３，４−ｂ］ピロール誘導体、その製造方法及び用途
US8461334B2 (en) Process for resolving zopiclone
CN1199968C (zh) 新的地洛他定盐、其合成方法及其药物组合物
WO2008035378A2 (en) An improved process for the preparation of thalidomide
CN100342851C (zh) 包含西布曲明甲磺酸盐半水合物晶体的药物组合物
CN1882526A (zh) 制备伏格列波糖的方法
CN1441802A (zh) 用以治疗阳痿的吡唑并嘧啶酮衍生物的制备方法
CN115974851A (zh) 2-氧代-3-氮杂双环[3.1.0]己烷衍生物
CN107998140B (zh) 化合物r1的用途
HK1042896A1 (zh) 吡啶并吡嗪化合物的新的盐及其结晶
CN1104239C (zh) 新颖的n－取代的吡咯烷衍生物及其制备方法
WO2013083014A1 (zh) 黄豆苷元衍生物、其药学上可接受的盐、制备方法以及包含其的药物组合物